NBTX
Nanobiotix (NBTX)
Healthcare • NASDAQ • $45.49+6.76%
- Symbol
- NBTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $45.49
- Daily Change
- +6.76%
- Market Cap
- $2.21B
- Trailing P/E
- N/A
- Forward P/E
- 308.45
- 52W High
- $45.60
- 52W Low
- $3.33
- Analyst Target
- $34.14
- Dividend Yield
- N/A
- Beta
- 0.58
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Company websiteResearch NBTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.